Lilly’s pancreatic cancer miss not a test of its biomarker strategy

The Phase III miss of Eli Lilly’s Armo-derived immuno-oncology asset in pancreatic cancer may have been a blow, but the pharma’s ongoing trials in lung cancer will be the ones to put its biomarker-based patient enrollment strategy to the test.

Eli Lilly and Co. (NYSE:LLY)

Read the full 457 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE